FDA approves Lupin's KCl for Oral Solution 20 mEq
27 November 2018 | News
It is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis.
Pharma company Lupin has announced that it has received approval for its Potassium Chloride for Oral Solution USP, 20 mEq from the United States Food and Drug Administration (FDA) to market a generic version of Pharma Research Software Solution LLC’s Potassium Chloride for Oral Solution, 20 mEq.
Lupin’s Potassium Chloride for Oral Solution USP, 20 mEq is the generic version of Pharma Research Software Solution, LLC’s Potassium Chloride for Oral Solution, 20 mEq.
It is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient.
Potassium Chloride for Oral Solution USP, 20 mEq had annual sales of approximately USD 105 million in the US (IQVIA MAT September 2018).
